BioGrowing Shines at Natural Products Expo West, Leading a New Trend of Health with Innovative Probiotic Solutions
Los Angeles, California--(Newsfile Corp. - March 8, 2025) - The highly anticipated Natural Products Expo West was grandly held from March 5th to 7th at the Anaheim Convention Center in Los Angeles, USA. As a top-tier event in the global natural and organic food sector, BioGrowing has been invited to participate for many years, showcasing its strength as a leading Chinese probiotic manufacturer to the world.
To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8722/243867_633d7669e4fa39ef_001full.jpg
Stepping into the BioGrowing booth, a fresh and natural style is immediately refreshing. The booth design is simple yet elegant, cleverly blending natural elements with a sense of technology, fully demonstrating BioGrowing's respect for nature and its persistent pursuit of health.
At this exhibition, BioGrowing highlighted its Flora-Focus® multi-functional probiotic series, which covers 9 major areas including gut health, oral health, immune support, weight management, virginal health, skin health, glycemic management, blood pressure improvement, and H. pylori suppression. In addition, BioGrowing also launched 6 functional solid beverages/capsules, and OralBubble™ probiotic microbubble Lozenge, which continue the high-quality standards while comprehensively upgrading the formula, taste, and dosage form to meet the increasingly diverse health needs of consumers.
To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8722/243867_633d7669e4fa39ef_002full.jpg
During the exhibition, BioGrowing launched a highly anticipated viganal health solution. Clinical studies have shown that BioGrowing's independently developed Lactobacillus crispatus LC-G22 combined with clotrimazole can significantly reduce the symptoms of recurrent vulvovaginal candidiasis (VVC), effectively inhibit the proliferation of pathogenic bacteria, and has good tolerance and safety, thereby regulating the vaginal microecological balance and enhancing the vagina's self-cleaning ability. Combined with Lactobacillus johnsonii LJ-G55 and Lacticaseibacillus rhamnosus Lr-G14 to inhibit the growth of Candida in the female private parts, it can provide women with a more comprehensive and effective private care solution.
To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8722/243867_633d7669e4fa39ef_003full.jpg
Another highlight is the Flora-Focus® weight management product. This product contains a complex of strains such as Lactiplantibacillus plantarum Lp-G18, Lactobacillus gasseri LG-G12, Lactiplantibacillus plantarum ZJUF T17, and Lactiplantibacillus plantarum ZJUF T34, which can effectively improve lipid metabolism, reduce the risk of abnormal blood lipids, and achieve scientific weight management. Currently, this product has been successfully applied in the fields of nutritional supplements, dairy products, and functional foods.
To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8722/243867_633d7669e4fa39ef_004full.jpg
The new OralBubble™ probiotic microbubble Lozenge also attracted much attention. This product uses a sugar-free formula with 10 billion live bacteria, consisting of 3 clinically proven strains and 3 plant essences, and is supported by patents from 5 countries and 10 efficacy literatures (including 3 clinical studies), which can solve 8 major oral health problems such as bad breath, gingivitis, and dental plaque in one stop.
To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8722/243867_633d7669e4fa39ef_005full.jpg
Since its establishment in 2006, BioGrowing has been committed to the exploration and innovation of probiotics, and has published more than 100 scientific research papers at home and abroad, and applied for more than 70 invention patents and utility model patents. As the TOP3 immune health probiotic supplier and TOP5 digestive health probiotic supplier in the Asia-Pacific region, BioGrowing's products have been exported to more than 80 countries around the world, covering 22 of the 27 EU countries.
To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8722/243867_633d7669e4fa39ef_006full.jpg
This appearance at Natural Products Expo West is a powerful declaration by BioGrowing to the global health industry. In the future, BioGrowing will continue to adhere to the brand vision of "Global Leader in Probiotic Raw Materials," continuously explore and innovate, and bring more healthy, safe, and effective probiotic products to global consumers, working together to create a new future for human health.
To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8722/243867_633d7669e4fa39ef_007full.jpg
Media contactCompany Name: BIOGROWING CO.,LTD.Contact: Echo SunEmail: cs@biogrowing.comPhone: +86 21 3920 5777Website: www.biogrowing.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/243867
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
32 minutes ago
- Yahoo
Is Beaten-Down Summit Therapeutics Stock a Bad-News Buy?
Summit Therapeutics stock fell hard recently in response to disappointing clinical trial results. Ivonescimab failed to produced a statistically significant overall survival benefit in the phase 3 Harmoni trial. Ivonescimab has been approved by Chinese regulators, but Summit Therapeutics has a license to sell it outside of China. 10 stocks we like better than Summit Therapeutics › Shares of Summit Therapeutics (NASDAQ: SMMT) tanked more than 30% on Friday, May 30. Such dramatic price swings aren't unusual in the biotechnology industry; in this case, disappointing data from an important clinical trial drove the stock down. Stock markets have a tendency to sell first and ask questions later. After watching this stock plummet, some bargain-shoppers are wondering if it fell too far. Recent trial results missed the mark the company was hoping for, but the results weren't entirely discouraging. Let's weigh the bad news against the good to see if this stock could be a beaten-down bargain. Summit Therapeutics and its investors have been eagerly anticipating results from the phase 3 Harmoni trial of ivonescimab. It's a bispecific antibody that works like a compination of Keytruda (a PD-1 inhibitor) plus Avastin (a VEGF inhibitor). Summit's stock price rocketed higher in 2024 thanks to Harmoni-2 trial results that showed it outperformed Keytruda at limiting tumor growth in lung cancer patients. Although ivonescimab is already approved in China, it's not for sale in the U.S. and EU, where Summit Therapeutics has a license to sell it. The Harmoni trial enrolled second-line lung cancer patients and treated them with ivonescimab or a placebo plus standard chemo. The treatment reduced the risk of disease progression in terms of tumor growth by 48%, but failed to show a convincing overall survival benefit. Adding ivonescimab to standard chemo reduced patients' risk of death by 21%, but the results fell just outside a 95% confidence interval with a p-value of 0.057. It's highly unlikely the Food and Drug Administration will approve ivonescimab for sale in the U.S. based on the Harmoni trial results. According to Summit, the FDA has been clear about the need for a statistically significant overall survival benefit to support an application. The China-based company that owns ivonescimab, Akeso, recently earned a second approval to market the therapy to lung cancer patients in China. Keytruda sales rose to $29.5 billion last year, and a treatment that can outperform the leader could do even better. Ivonescimab is unlikely to earn approval in the U.S. for patients similar to those enrolled in the Harmoni trial. Given its ability to shrink tumors, though, it's probably just a matter of time before it produces statistically significant overall survival results for an underserved patient population. Tumor responses get attention, but oncologists are far more interested in giving patients a chance for long-term survival. Keytruda's a top seller now because it produced dramatic overall survival results, compared to the standard treatments of its time. The lack of convincing overall survival data so far for ivonescimab severely reduces the odds that it will go on to produce blockbuster sales in the places where Summit Therapeutics has a license to sell it. Despite the obvious challenges ahead, expectations are still sky-high. Drugmaker stocks tend to trade at mid-single-digit multiples of trailing annual sales. Summit has no sales, as ivonescimab is the only candidate in its pipeline. Despite the lack of options and an uncertain path forward, the stock finished May with a market cap above $13.5 billion. If ivonescimab goes on to produce sales anywhere near Keytruda's, investors who bought Summit Therapeutics at recent prices could reap enormous gains. Unfortunately, the Harmoni trial's failure to produce a convincing overall survival benefit suggests that future sales will be muted, even if the company can get it past the FDA. It's probably best to watch this story play out from a safe distance. Before you buy stock in Summit Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Summit Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $651,049!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $828,224!* Now, it's worth noting Stock Advisor's total average return is 979% — a market-crushing outperformance compared to 171% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of May 19, 2025 Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Summit Therapeutics. The Motley Fool has a disclosure policy. Is Beaten-Down Summit Therapeutics Stock a Bad-News Buy? was originally published by The Motley Fool Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
Woman lost 6st bodybuilding after 'hating' final photo with late dad
A woman who gained five stone whilst caring for her terminally ill father has shed the weight to become a bodybuilder after being unable to look at her final photo with him. Ellie Crabtree, 22, turned to food 'for comfort' after her dad Geoff's, 59, terminal bone cancer diagnosis in July 2022. With 'no structure' to her diet, Ellie would gorge on foods Chinese takeaways and ballooned to 15st 5lb. After her dad passed away in October 2022, Ellie began her weight loss journey after struggling to look at the final photo she had with him. She lost four stone naturally before enquiring about bodybuilding training at her local gym, where she lost a further two stone to become a svelte 9st 3lb. She went on to place second in the British finals at NABBA bodybuilding competition in Bradford, in May 2024. Since then, Ellie has been dealing with 'unresolved trauma' and has learnt how to maintain her weight healthily. Diet before: Breakfast - Nothing Lunch - A sandwich Dinner - Takeaway like Chinese Snacks - Chocolate Diet now: Breakfast - Oats with fruit and Greek yoghurt or bacon, egg and avocado Lunch - Chicken or prawn salad with cottage cheese Dinner - Chicken fajita salads with wraps or homemade burgers Snacks - Greek yoghurt bowls with nut butters and fruit, baked oats, chocolate rice cakes
Business Wire
5 hours ago
- Business Wire
CARMAT Announces the First Commercial Implants of Its Aeson® Artificial Heart Outside the European Union
PARIS--(BUSINESS WIRE)--Regulatory News: CARMAT (FR0010907956, ALCAR), designer and developer of the world's most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from advanced biventricular heart failure (the ' Company ' or ' CARMAT '), today announces the first implants of its Aeson® artificial heart in a commercial set-up, outside the European Union (EU). Two implants of Aeson® artificial heart were performed during the week commencing May 26, 2025 in Israel. The first one was carried out at Hadassah Ein Kerem Hospital in Jerusalem by a team led by Pr Offer Amir, Pr Rabea Asleh and Dr Amit Korach, respectively director of the Heart Institute, director of heart failure unit and director of the cardiac surgery department at Hadassah Medical Center. The second one was carried out at Sheba Medical Center in Ramat Gan (Tel Aviv), by a team led by Dr Jeff Morgan, Dr Leonid Sternik, Dr Alex Fardman and Dr Eyal Nachum, respectively head of mechanical support unit, director of cardiac surgery department, heart failure cardiologist and cardiac transplant surgeon. Those are the first Aeson® implants made in a commercial set-up outside the European Union. These implants bring to 5 the total number of countries 1 where commercial implants have been performed so far. They confirm the trust placed in the device by healthcare professionals, and the growing interest in the therapy. About CARMAT CARMAT is a French MedTech that designs, manufactures and markets the Aeson ® artificial heart. The Company's ambition is to make Aeson ® the first alternative to a heart transplant, and thus provide a therapeutic solution to people suffering from end-stage biventricular heart failure, who are facing a well-known shortfall in available human grafts. The world's first physiological artificial heart that is highly hemocompatible, pulsatile and self-regulated, Aeson ® could save, every year, the lives of thousands of patients waiting for a heart transplant. The device offers patients quality of life and mobility thanks to its ergonomic and portable external power supply system that is continuously connected to the implanted prosthesis. Aeson ® is commercially available as a bridge to transplant in the European Union and other countries that recognize CE marking. Aeson ® is also currently being assessed within the framework of an Early Feasibility Study (EFS) in the United States. Founded in 2008, CARMAT is based in the Paris region, with its head offices located in Vélizy-Villacoublay and its production site in Bois-d'Arcy. The Company can rely on the talent and expertise of a multidisciplinary team of circa 200 highly specialized people. CARMAT is listed on the Euronext Growth market in Paris (Ticker: ALCAR / ISIN code: FR0010907956). For more information, please go to and follow us on LinkedIn. Disclaimer This press release and the information it contains do not constitute an offer to sell or subscribe, nor a solicitation of an offer to buy or subscribe, for CARMAT shares in any country. This press release may contain forward-looking statements regarding the Company's objectives and outlook. These forward-looking statements are based on the current estimates and anticipations of the Company's management and are subject to risk factors and uncertainties, including those described in its Universal Registration Document filed with the French Financial Markets Authority (Autorité des marchés financiers) (the 'AMF') under number D.25-0345 (the ' 2024 Universal Registration Document '), available free of charge on the websites of CARMAT ( and the AMF ( Readers' attention is particularly drawn to the fact that the Company's current cash runway is limited to mid-June 2025 (excluding the flexible equity financing line entered into with IRIS, which was announced on March 27, 2025). The Company is also subject to other risks and uncertainties, such as its ability to implement its strategy, the pace of development of its production and sales, the pace and results of ongoing or planned clinical trials, technological evolution and competitive environment, regulatory changes, industrial risks, and all risks associated with the Company's growth management. The Company's forward-looking statements mentioned in this press release may not be achieved due to these elements or other risk factors and uncertainties, whether unknown or not considered material and specific by the Company as of today. Aeson® is an active implantable medical device commercially available in the European Union and other countries recognising the CE mark. The Aeson® total artificial heart is intended to replace the ventricles of the native heart and is indicated as a bridge to transplant in patients with end-stage biventricular heart failure (Intermacs classes 1-4) who cannot benefit from maximal medical therapy or a left ventricular assist device (LVAD) and who are likely to benefit from a heart transplant within 180 days of implantation. The decision to implant and the surgical procedure must be carried out by healthcare professionals trained by the manufacturer. The documentation (clinician's manual, patient's manual and alarm booklet) must be read carefully to learn about the characteristics of Aeson® and the information required for patient selection and proper use (contraindications, precautions, side effects) of Aeson®. In the United States, Aeson® is currently only available as part of a feasibility clinical trial approved by the Food & Drug Administration (FDA).
